Cellectar Biosciences, Inc. (CLRB)

Cellectar Biosciences, Inc. (CLRB) Healthcare & Pipeline Overview

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company pioneering phospholipid drug conjugate (PDC) therapies for cancer. Its lead drug, CLR 131, targets relapsed or refractory hematologic malignancies and solid tumors, positioning it in the competitive oncology therapeutics market with ongoing clinical trials.

What Is the Investment Thesis for CLRB?

Cellectar Biosciences presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's PDC platform offers a novel approach to targeted cancer therapy, potentially improving efficacy and reducing toxicity compared to traditional chemotherapy. The ongoing Phase 2 clinical trials for CLR 131 in r/r Waldenstrom's macroglobulinemia and multiple myeloma represent key value drivers, with positive data readouts potentially leading to accelerated regulatory approval and commercialization. Successful development of CLR 1900 and advancement of collaborative PDC programs could further expand the company's pipeline and revenue streams. However, the company's small market capitalization of $8.65M and limited resources pose significant challenges, including dependence on successful clinical trial outcomes and the ability to secure additional funding. The medium AI risk rating reflects the inherent uncertainty in clinical-stage biotechnology companies.

Based on FMP financials and quantitative analysis

CLRB Key Highlights

• Lead drug candidate CLR 131 is in Phase 2 clinical trials for r/r Waldenstrom's macroglobulinemia and B-cell malignancies.
• CLR 131 is also in a Phase 2B clinical study for r/r multiple myeloma (MM) patients.
• Phase I study underway for CLR 131 in various pediatric cancers, r/r head and neck cancers, and R/R MM.
• Developing CLR 1900, a PDC chemotherapeutic program in the preclinical stage, targeting solid tumors.
• Collaborative PDC programs with Avicenna Oncology GMBH, Orano Med, IntoCell Inc, and LegoChemBio to expand research and development efforts.

Who Are CLRB's Competitors?

CLRB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CLRB's Key Strengths?

• Proprietary PDC technology platform.
• Clinical data supporting the potential of CLR 131.
• Experienced management team.
• Collaborative partnerships with other companies.

What Are CLRB's Weaknesses?

• Limited financial resources.
• Dependence on successful clinical trial outcomes.
• Competition from established pharmaceutical companies.
• Small number of employees.

What Could Drive CLRB Stock Higher?

• Data readouts from Phase 2 clinical trials of CLR 131 in r/r Waldenstrom's macroglobulinemia and multiple myeloma.
• Initiation of new clinical trials for CLR 131 in other cancer types.
• Advancement of CLR 1900 into preclinical development.
• Expansion of collaborative PDC programs with other companies.

What Are the Key Risks for CLRB?

• Financial-distress signal — its Altman Z-Score of -39.47 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays.
• Regulatory setbacks or rejection of drug candidates.
• Competition from other cancer therapies.
• Dependence on securing additional funding.
• Patent expirations and intellectual property challenges.

What Are the Growth Opportunities for CLRB?

• Advancement of CLR 131 in Waldenstrom's Macroglobulinemia: The market for Waldenstrom's macroglobulinemia treatment is estimated to grow, driven by the need for more effective and less toxic therapies. Positive Phase 2 clinical trial results for CLR 131 could lead to accelerated regulatory approval and commercialization, capturing a significant share of this market. This represents a near-term growth opportunity with potential for orphan drug designation and market exclusivity.
• Expansion of CLR 131 into Multiple Myeloma: Multiple myeloma is a large and growing market with significant unmet needs. Cellectar's Phase 2B clinical study of CLR 131 in r/r multiple myeloma patients could open a substantial revenue stream. Success in this indication would position CLR 131 as a valuable treatment option for patients who have failed other therapies.
• Development of CLR 1900 for Solid Tumors: The solid tumor market represents a vast opportunity for Cellectar. The preclinical development of CLR 1900, a PDC chemotherapeutic program, could lead to a new generation of targeted therapies for various solid tumor types. This represents a long-term growth opportunity with significant potential for market expansion.
• Strategic Collaborations and Partnerships: Cellectar's collaborative PDC programs with Avicenna Oncology GMBH, Orano Med, IntoCell Inc, and LegoChemBio provide opportunities to expand its research and development efforts and access new markets. These partnerships could lead to the development of novel PDC therapies and generate revenue through licensing agreements and milestone payments.
• Expansion into Pediatric Cancers: The Phase I study of CLR 131 in various pediatric cancers represents an opportunity to address unmet needs in this vulnerable population. Positive clinical data could lead to regulatory approval and commercialization, providing a valuable treatment option for children with cancer. This also offers the potential for orphan drug designation and market exclusivity.

What Opportunities Does CLRB Have?

• Accelerated regulatory approval pathways for CLR 131.
• Expansion of CLR 131 into new indications.
• Development of new PDC therapies for other cancer types.
• Strategic acquisitions or partnerships.

What Threats Does CLRB Face?

• Clinical trial failures.
• Regulatory setbacks.
• Competition from new therapies.
• Patent expirations.

What Are CLRB's Competitive Advantages?

• Proprietary phospholipid drug conjugate (PDC) platform.
• Patent protection for CLR 131 and other PDC candidates.
• Clinical data supporting the safety and efficacy of CLR 131.
• Strategic collaborations with other companies.

What Does CLRB Do?

Founded in 2002 and headquartered in Florham Park, New Jersey, Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative drugs for the treatment of cancer. The company's core technology revolves around its proprietary phospholipid drug conjugate (PDC) platform, designed to deliver cytotoxic payloads directly to cancer cells while minimizing systemic toxicity. Cellectar's lead PDC candidate, CLR 131 (iopofosine I-131), is currently in Phase 2 clinical trials for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies, as well as a Phase 2B clinical study in r/r multiple myeloma (MM) patients. Additionally, CLR 131 is in a Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM, showcasing its potential across a range of cancer types. Beyond CLR 131, Cellectar is developing CLR 1900, a PDC chemotherapeutic program in the preclinical stage, targeting solid tumors. The company also engages in collaborative PDC programs, including partnerships with Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, IntoCell Inc, and LegoChemBio, expanding its research and development efforts through strategic alliances.

What Products and Services Does CLRB Offer?

• Develop phospholipid drug conjugate (PDC) therapies for cancer treatment.
• Conduct clinical trials to evaluate the safety and efficacy of CLR 131 in various hematologic malignancies and solid tumors.
• Develop CLR 1900, a PDC chemotherapeutic program targeting solid tumors.
• Collaborate with other companies to expand research and development efforts.
• Seek regulatory approvals for its drug candidates from the FDA and other regulatory agencies.
• Commercialize approved therapies to generate revenue.

How Does CLRB Make Money?

• Develop proprietary PDC technology for targeted cancer therapy.
• Out-license or co-develop PDC assets with partners.
• Generate revenue through product sales, licensing agreements, and milestone payments.
• Secure funding through equity offerings, debt financing, and government grants.

What Industry Does CLRB Operate In?

Cellectar Biosciences operates within the competitive biotechnology industry, focusing on oncology therapeutics. The market for cancer treatments is substantial and growing, driven by an aging population and advancements in diagnostic technologies. The company's PDC platform represents a novel approach to targeted drug delivery, potentially offering advantages over traditional chemotherapy and other targeted therapies. However, Cellectar faces competition from established pharmaceutical companies and other biotechnology firms developing innovative cancer treatments. Success in this market requires strong clinical data, regulatory approvals, and effective commercialization strategies.

Who Are CLRB's Key Customers?

• Patients with relapsed or refractory hematologic malignancies and solid tumors.
• Hospitals and oncology clinics.
• Pharmaceutical companies through licensing and collaboration agreements.

How Cellectar Biosciences, Inc. Is Valued

Cellectar Biosciences, Inc. carries a market capitalization of $8.65M, placing it in the micro-cap category. Relative to its peer group, CLRB's quantitative score of 26/100 is below the peer average of 76/100.

Company Profile

Cellectar Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Florham Park, US. The company is led by CEO James V. Caruso. CLRB has traded publicly since 2005.

Key Financial Metrics

A current ratio of 1.90 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -176.8%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 1/9Financial Health

Cellectar Biosciences, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -39.47 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Cellectar Biosciences, Inc. revenue of about $3.8M for fiscal 2026, with EPS near $-2.05. The estimate reflects 3 contributing analysts.

Net buyingInsider Activity

Over the past six months, Cellectar Biosciences, Inc. insiders filed 4 SEC Form 4 transactions — 0 sales and 4 purchases. On net that is roughly 69K shares acquired (about $200K) — insiders putting money in tends to read as conviction.

CLRB Financials

CLRB Latest News

CLRB Analyst Consensus

CLRB MoonshotScore

What Investors Ask About Cellectar Biosciences, Inc. (CLRB) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources